应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
HAE 美国血液技术
未开盘 09-09 16:00:00 EDT
103.16
+0.32
+0.31%
盘后
103.16
+0.00
0.00%
19:30 EDT
最高
103.18
最低
100.57
成交量
61.22万
今开
102.15
昨收
102.84
日振幅
2.54%
总市值
46.88亿
流通市值
46.01亿
总股本
4,545万
成交额
6,284万
换手率
1.37%
流通股本
4,460万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
美国血液技术公司:CSL或将采用其Nexsys PCS设备与Persona Plus技术,并采购美国市场相关耗材——SEC文件披露
美股速递 · 08-18
美国血液技术公司:CSL或将采用其Nexsys PCS设备与Persona Plus技术,并采购美国市场相关耗材——SEC文件披露
美国血液技术公司公布2027财年第一季度财报,投资者关系网站已上线
美股速递 · 08-06
美国血液技术公司公布2027财年第一季度财报,投资者关系网站已上线
KalVista新数据揭示注射治疗给幼儿HAE患者带来沉重负担
环球市场播报 · 05-28
KalVista新数据揭示注射治疗给幼儿HAE患者带来沉重负担
异动解读 | 美国血液技术盘前大涨8.22%,因调整2027财年业绩指引
异动解读 · 05-07
异动解读 | 美国血液技术盘前大涨8.22%,因调整2027财年业绩指引
美国血液技术公司调整2027财年指引:摊薄后每股调整后收益与营收增长相若
美股速递 · 05-07
美国血液技术公司调整2027财年指引:摊薄后每股调整后收益与营收增长相若
美国血液技术公布2026财年第四季度财报 投资者关系网站可查阅
美股速递 · 05-07
美国血液技术公布2026财年第四季度财报 投资者关系网站可查阅
美国血液技术Vascade MVP® XL静脉血管闭合系统获FDA扩大适应症批准
美股速递 · 03-31
美国血液技术Vascade MVP® XL静脉血管闭合系统获FDA扩大适应症批准
美国血液技术盘中异动 下午盘急速上涨5.00%报66.17美元
市场透视 · 2025-02-25
美国血液技术盘中异动 下午盘急速上涨5.00%报66.17美元
异动解读 | 美国血液技术公司股价盘中大跌5.25% 分析师下调评级预期所致
异动解读 · 2025-02-08
异动解读 | 美国血液技术公司股价盘中大跌5.25% 分析师下调评级预期所致
美国血液技术盘中异动 下午盘大幅跳水5.06%报59.80美元
市场透视 · 2025-02-08
美国血液技术盘中异动 下午盘大幅跳水5.06%报59.80美元
摩根大通证券公司:维持Haemonetics(HAE.US)评级,由优于大市调整至优于大市评级, 目标价由125.00美元调整至100.00美元。
金融界 · 2025-02-08
摩根大通证券公司:维持Haemonetics(HAE.US)评级,由优于大市调整至优于大市评级, 目标价由125.00美元调整至100.00美元。
雷蒙德詹姆斯公司:重申Haemonetics(HAE.US)评级,由强烈买入调整至强烈买入评级, 目标价由120.00美元调整至115.00美元。
金融界 · 2025-02-08
雷蒙德詹姆斯公司:重申Haemonetics(HAE.US)评级,由强烈买入调整至强烈买入评级, 目标价由120.00美元调整至115.00美元。
异动解读 | 美国血液技术因下调业绩预期 盘中一度大跌近11%
异动解读 · 2025-02-06
异动解读 | 美国血液技术因下调业绩预期 盘中一度大跌近11%
美国血液技术盘中异动 急速下跌8.80%报64.97美元
市场透视 · 2025-02-06
美国血液技术盘中异动 急速下跌8.80%报64.97美元
Haemonetics 2025年第三季度调整后每股收益$1.19超出预期$1.17,销售额$3.49亿低于预期$3.5293亿
财报速递 · 2025-02-06
Haemonetics 2025年第三季度调整后每股收益$1.19超出预期$1.17,销售额$3.49亿低于预期$3.5293亿
美国血液技术盘中异动 临近收盘急速拉升5.08%
市场透视 · 2025-02-05
美国血液技术盘中异动 临近收盘急速拉升5.08%
美国血液技术盘中异动 早盘急速下跌5.00%报71.30美元
市场透视 · 2025-01-16
美国血液技术盘中异动 早盘急速下跌5.00%报71.30美元
美国血液技术盘中异动 快速下跌5.20%报75.81美元
市场透视 · 2025-01-16
美国血液技术盘中异动 快速下跌5.20%报75.81美元
美国血液技术2024财年第三财季实现净利润33.83百万美元,同比增加35.81%
市场透视 · 2024-11-17
美国血液技术2024财年第三财季实现净利润33.83百万美元,同比增加35.81%
异动解读 | 美国血液技术财报超预期 股价大涨近8%
异动解读 · 2024-11-08
异动解读 | 美国血液技术财报超预期 股价大涨近8%
加载更多
公司概况
公司名称:
美国血液技术
所属市场:
NYSE
上市日期:
--
主营业务:
Haemonetics Corporation于1971年根据马萨诸塞州法律成立,是一家医疗器械公司。该公司是一家致力于提高医疗保健质量、效果和效率的全球医疗技术公司,运营三个主要报告分部:血浆、血库和医院。公司的创新解决方案包括医院技术、端到端血浆采集技术以及帮助血库采集急需血液成分的产品。
发行价格:
--
{"stockData":{"symbol":"HAE","market":"US","secType":"STK","nameCN":"美国血液技术","latestPrice":103.16,"timestamp":1788984000000,"preClose":102.84,"halted":0,"volume":612215,"hourTrading":{"tag":"盘后","latestPrice":103.16,"preClose":103.16,"latestTime":"19:30 EDT","volume":9409,"amount":970638.74,"timestamp":1788996604595,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.003111629716063722,"floatShares":44597205,"shares":45446000,"eps":2.05,"marketStatus":"未开盘","change":0.32,"latestTime":"09-09 16:00:00 EDT","open":102.15,"high":103.18,"low":100.57,"amount":62841720.87535,"amplitude":0.025379,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.05,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789027200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":673761600000,"exchange":"NYSE","adjPreClose":102.84,"preHourTrading":{"tag":"盘前","latestPrice":102.01,"preClose":102.84,"latestTime":"09:28 EDT","volume":947,"amount":97140.17278000001,"timestamp":1788960528071,"change":-0.83,"changeRate":-0.008071,"amplitude":0.011571},"postHourTrading":{"tag":"盘后","latestPrice":103.16,"preClose":103.16,"latestTime":"19:30 EDT","volume":9409,"amount":970638.74,"timestamp":1788996604595,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.013583,"impliedVol":0.3847,"impliedVolPercentile":0.2311},"requestUrl":"/m/hq/s/HAE","defaultTab":"news","newsList":[{"id":"1103447654","title":"美国血液技术公司:CSL或将采用其Nexsys PCS设备与Persona Plus技术,并采购美国市场相关耗材——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1103447654","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103447654?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:12","pubTimestamp":1787047948,"startTime":"0","endTime":"0","summary":"美国血液技术公司(Haemonetics)最新提交的SEC文件显示,CSL可能将在美国境内使用该公司搭载Persona Plus技术的Nexsys PCS设备,并采购与之配套的一次性耗材。\n这一消息源自美国血液技术公司向美国证券交易委员会(SEC)提交的正式文件。文件内容明确提及,CSL方面有望将上述设备及耗材投入美国市场的实际应用。对于血液技术领域而言,这一潜在合作动向值得密切关注——它既关乎设备端的部署,也牵动耗材端的持续供应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64QTZ34.USD","IE0034390439.USD","LU0205193047.USD","LU0106261612.USD","IE00B19Z6F94.USD","HAE","IE00BLDYK493.USD","LU1169590202.USD","BK4198","LU0205194284.USD","LU1169589451.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154406193","title":"美国血液技术公司公布2027财年第一季度财报,投资者关系网站已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=1154406193","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154406193?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:03","pubTimestamp":1786010636,"startTime":"0","endTime":"0","summary":"美国血液技术公司(Haemonetics)正式发布了2027财年第一季度的财务业绩。目前,这些详细数据已在其投资者关系网站上公开披露,供广大投资者及市场关注者查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","LU0106261612.USD","LU1169589451.USD","IE00BLDYK493.USD","LU0205193047.USD","LU0012050646.USD","BK4198","IE00B19Z6F94.USD","IE00B64QTZ34.USD","IE0034390439.USD","LU1169590202.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692388","title":"KalVista新数据揭示注射治疗给幼儿HAE患者带来沉重负担","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692388","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638692388?lang=zh_cn&edition=full","pubTime":"2026-05-28 23:16","pubTimestamp":1779981360,"startTime":"0","endTime":"0","summary":"KalVista Pharmaceuticals周四在2026年国际药物经济学与结果研究学会年会及东部过敏会议上公布的新数据显示,针对2至11岁遗传性血管性水肿患儿,现有按需注射治疗方案给患者及其照护者带来了显著负担。 KalVista首席执行官Ben Palleiko表示,这些数据凸显了HAE患儿及其家庭面临的巨大未满足需求,强化了市场对易于使用、能支持早期和持续治疗的新选项的需求。 目前,KalVista正推进其口服药物Sebetralstat在2至11岁患儿中的KONFIDENT-KID试验,并计划在2026年第三季度提交新药上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-28/doc-inhznkum8089579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4198","LU0205193047.USD","LU1169589451.USD","LU0012050646.USD","HAE","IE00B64QTZ34.USD","LU0106261612.USD","IE00BLDYK493.USD","IE0034390439.USD","LU1169590202.USD","LU0205194284.USD","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160022193","title":"异动解读 | 美国血液技术盘前大涨8.22%,因调整2027财年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1160022193","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160022193?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:40","pubTimestamp":1778157600,"startTime":"0","endTime":"0","summary":"美国血液技术(HAE)今日盘前股价大涨8.22%,引起了市场的广泛关注。消息面上,公司最新提交的SEC文件显示,其对2027财年业绩指引作出了重要调整,预计摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配,增强了投资者对公司未来盈利前景的信心。摊薄后每股收益作为衡量企业盈利能力的关键指标,其与营收增长的协同变化,通常被视为企业运营效率的重要参考依据。此次指引调整可能被视为公司管理层对未来增长持乐观态度的信号,从而推动了股价的积极反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117554142","title":"美国血液技术公司调整2027财年指引:摊薄后每股调整后收益与营收增长相若","url":"https://stock-news.laohu8.com/highlight/detail?id=1117554142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117554142?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:16","pubTimestamp":1778148978,"startTime":"0","endTime":"0","summary":"美国血液技术公司(Haemonetics)在最新提交的SEC文件中,对2027财年业绩指引作出重要调整。根据披露信息,公司预计2027财年摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。\n这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配。摊薄后每股收益作为衡量企业盈利能力的关键指标,其与营收增长的协同变化,通常被视为企业运营效率的重要参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64QTZ34.USD","LU1169589451.USD","IE00BLDYK493.USD","HAE","LU0106261612.USD","LU0205194284.USD","LU0205193047.USD","LU1169590202.USD","LU0012050646.USD","BK4198","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154846917","title":"美国血液技术公布2026财年第四季度财报 投资者关系网站可查阅","url":"https://stock-news.laohu8.com/highlight/detail?id=1154846917","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154846917?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:01","pubTimestamp":1778148075,"startTime":"0","endTime":"0","summary":"美国血液技术公司(Haemonetics Corporation)已发布其2026财年第四季度财务业绩报告。相关财务数据及详细信息现可通过公司投资者关系网站进行查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","LU0012050646.USD","LU0205194284.USD","IE00B64QTZ34.USD","IE0034390439.USD","IE00B19Z6F94.USD","BK4198","LU0106261612.USD","LU0205193047.USD","HAE","LU1169589451.USD","IE00BLDYK493.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115190387","title":"美国血液技术Vascade MVP® XL静脉血管闭合系统获FDA扩大适应症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1115190387","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115190387?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:16","pubTimestamp":1774901781,"startTime":"0","endTime":"0","summary":"美国血液技术公司宣布,其Vascade MVP® XL静脉血管闭合系统已获得美国食品药品监督管理局的扩大标签使用批准。这一监管里程碑意味着该创新器械的应用范围将进一步拓展,为更多患者提供微创手术后的血管闭合解决方案。\n此次标签扩展彰显了公司在血管闭合技术领域的持续创新能力,也为临床医生提供了更灵活的手术工具选择。该系统采用独特的闭合机制,能够有效提升手术效率并降低并发症风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64QTZ34.USD","LU0106261612.USD","LU0205194284.USD","BK4198","IE00B19Z6F94.USD","LU0205193047.USD","LU0012050646.USD","LU1169590202.USD","IE00BLDYK493.USD","LU1169589451.USD","IE0034390439.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514086737","title":"美国血液技术盘中异动 下午盘急速上涨5.00%报66.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514086737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514086737?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:53","pubTimestamp":1740426800,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时53分,美国血液技术股票出现异动,股价快速拉升5.00%。截至发稿,该股报66.17美元/股,成交量38.3166万股,换手率0.76%,振幅5.12%。美国血液技术股票所在的医疗设备行业中,整体涨幅为0.25%。其相关个股中,Anbio Biotechnology、奥瑞许科技、美国血液技术涨幅较大,Sharps Technology Inc.、Glucotrack, Inc.、Microbot Medical Inc.较为活跃,换手率分别为44.95%、6.01%、5.07%,振幅较大的相关个股有Sharps Technology Inc.、Nexgel Inc C/Wts 27/12/2026 、Precision Optics Corporation, Inc.,振幅分别为23.85%、15.98%、14.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035320a25257e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035320a25257e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4198","LU1169590202.USD","IE00B64QTZ34.USD","IE00BLDYK493.USD","LU0205193047.USD","HAE","LU0012050646.USD","LU0106261612.USD","LU0205194284.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155255330","title":"异动解读 | 美国血液技术公司股价盘中大跌5.25% 分析师下调评级预期所致","url":"https://stock-news.laohu8.com/highlight/detail?id=1155255330","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155255330?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:26","pubTimestamp":1738956391,"startTime":"0","endTime":"0","summary":"美国血液技术公司今日盘中股价大跌5.25%,引发了市场的广泛关注。根据相关新闻报道,导致该公司股价下跌的主要原因是分析师对其未来前景的预期下调。知名投资银行摩根大通证券公司今日维持了对美国血液技术的\"优于大市\"评级,但将公司的目标股价从125美元下调至100美元。美国血液技术公司主要从事血液和血浆成分采集、加工和输送,业务分为血浆、血液中心和医院三个分部。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 美国血液技术公司股价盘中大跌5.25% 分析师下调评级预期所致","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509778144","title":"美国血液技术盘中异动 下午盘大幅跳水5.06%报59.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509778144","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509778144?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:15","pubTimestamp":1738955721,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日03时15分,美国血液技术股票出现波动,股价快速下跌5.06%。截至发稿,该股报59.80美元/股,成交量146.523万股,换手率2.92%,振幅6.33%。美国血液技术股票所在的医疗设备行业中,整体跌幅为0.68%。美国血液技术公司简介:美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案,改善患者护理,降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208031521a23d5d8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208031521a23d5d8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HAE","IE00BLDYK493.USD","IE00B64QTZ34.USD","LU1169589451.USD","LU0205194284.USD","LU0106261612.USD","LU0205193047.USD","LU0012050646.USD","LU1169590202.USD","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509729791","title":"摩根大通证券公司:维持Haemonetics(HAE.US)评级,由优于大市调整至优于大市评级, 目标价由125.00美元调整至100.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509729791","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509729791?lang=zh_cn&edition=full","pubTime":"2025-02-08 01:02","pubTimestamp":1738947740,"startTime":"0","endTime":"0","summary":"摩根大通证券公司:维持Haemonetics(HAE.US)评级,由优于大市调整至优于大市评级, 目标价由125.00美元调整至100.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08010248031451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HAE","399975","159848"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509572976","title":"雷蒙德詹姆斯公司:重申Haemonetics(HAE.US)评级,由强烈买入调整至强烈买入评级, 目标价由120.00美元调整至115.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509572976","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509572976?lang=zh_cn&edition=full","pubTime":"2025-02-08 01:02","pubTimestamp":1738947740,"startTime":"0","endTime":"0","summary":"雷蒙德詹姆斯公司:重申Haemonetics(HAE.US)评级,由强烈买入调整至强烈买入评级, 目标价由120.00美元调整至115.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08010248031449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111478372","title":"异动解读 | 美国血液技术因下调业绩预期 盘中一度大跌近11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111478372","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111478372?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:42","pubTimestamp":1738856552,"startTime":"0","endTime":"0","summary":"美国医疗设备制造商美国血液技术(HAE)2月6日盘中一度大跌10.74%,引发市场关注。\n\n公司当天公布下调了2025财年的预期销售增长率,从此前的5%-8%下调至3%-5%,这是导致该股大跌的主因。同时,公司第三季度的营收3.49亿美元也低于分析师预期的3.53亿美元。\n\n美国血液技术主营业务包括血液和血浆成分采集、外科手术室和医院输血服务等。公司去年第三季度每股利润1.19美元高于市场预期,但由于业绩预期的下调,导致投资者对其长期增长前景持谨慎态度。该股过去12个月股价已下跌约17%。机构评级显示,82%的分析师给予买入评级,主要看好其血浆和医院业务增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509774312","title":"美国血液技术盘中异动 急速下跌8.80%报64.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774312","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509774312?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852370,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分,美国血液技术股票出现波动,股价快速下挫8.80%。截至发稿,该股报64.97美元/股,成交量2.4341万股,换手率0.05%,振幅1.01%。美国血液技术股票所在的医疗设备行业中,整体跌幅为0.19%。美国血液技术公司简介:美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案,改善患者护理,降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223250a23bce9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223250a23bce9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0205193047.USD","BK4198","LU0012050646.USD","HAE","IE00BLDYK493.USD","LU1169589451.USD","LU1169590202.USD","LU0106261612.USD","IE00B64QTZ34.USD","LU0205194284.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104450572","title":"Haemonetics 2025年第三季度调整后每股收益$1.19超出预期$1.17,销售额$3.49亿低于预期$3.5293亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1104450572","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104450572?lang=zh_cn&edition=full","pubTime":"2025-02-06 19:26","pubTimestamp":1738841182,"startTime":"0","endTime":"0","summary":"Haemonetics报告季度每股收益为$1.19,高于分析师预期的$1.17,比预期高出1.71%。这是比去年同期每股收益$1.04增加了14.42%。公司报告季度销售额为$3.49亿,低于分析师预期的$3.5293亿,低1.11%。以上内容来自Benzinga Earnings专栏,原文如下:Haemonetics reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.17 by 1.71 percent. This is a 14.42 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $349.00 million which missed the analyst consensus estimate of $352.93 million by 1.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Haemonetics 2025年第三季度调整后每股收益$1.19超出预期$1.17,销售额$3.49亿低于预期$3.5293亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509499545","title":"美国血液技术盘中异动 临近收盘急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509499545","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509499545?lang=zh_cn&edition=full","pubTime":"2025-02-05 04:39","pubTimestamp":1738701572,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日04时39分,美国血液技术股票出现波动,股价大幅上涨5.08%。截至发稿,该股报69.51美元/股,成交量64.9685万股,换手率1.29%,振幅5.19%。美国血液技术股票所在的医疗设备行业中,整体涨幅为0.06%。美国血液技术公司简介:美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案,改善患者护理,降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205043932abc26b39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205043932abc26b39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0012050646.USD","LU1169590202.USD","IE00B64QTZ34.USD","LU0205193047.USD","LU0106261612.USD","BK4198","LU1169589451.USD","IE00BLDYK493.USD","LU0205194284.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503916280","title":"美国血液技术盘中异动 早盘急速下跌5.00%报71.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916280","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503916280?lang=zh_cn&edition=full","pubTime":"2025-01-16 22:52","pubTimestamp":1737039121,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日22时52分,美国血液技术股票出现异动,股价大幅下跌5.00%。截至发稿,该股报71.30美元/股,成交量7.6882万股,换手率0.15%,振幅4.88%。美国血液技术股票所在的医疗设备行业中,整体跌幅为0.29%。美国血液技术公司简介:美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案,改善患者护理,降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116225201abad54a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116225201abad54a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0012050646.USD","LU1169590202.USD","IE00B64QTZ34.USD","LU0205193047.USD","LU0106261612.USD","BK4198","LU1169589451.USD","IE00BLDYK493.USD","LU0205194284.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503467660","title":"美国血液技术盘中异动 快速下跌5.20%报75.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503467660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503467660?lang=zh_cn&edition=full","pubTime":"2025-01-16 02:57","pubTimestamp":1736967463,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日02时57分,美国血液技术股票出现异动,股价快速下跌5.20%。截至发稿,该股报75.81美元/股,成交量21.8465万股,换手率0.43%,振幅7.82%。美国血液技术股票所在的医疗设备行业中,整体涨幅为4.11%。美国血液技术公司简介:美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案,改善患者护理,降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011602574398677495&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011602574398677495&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","IE00BLDYK493.USD","LU0012050646.USD","IE00B64QTZ34.USD","LU1169589451.USD","LU0205193047.USD","LU0205194284.USD","BK4198","LU0106261612.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484510190","title":"美国血液技术2024财年第三财季实现净利润33.83百万美元,同比增加35.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484510190","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484510190?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:00","pubTimestamp":1731772808,"startTime":"0","endTime":"0","summary":"11月17日,美国血液技术公布财报,公告显示公司2024财年第三财季净利润为33.83百万美元,同比增加35.81%;其中营业收入为3.46亿美元,同比增加8.81%,每股基本收益为0.66美元。从资产负债表来看,美国血液技术总负债16.46亿美元,其中短期债务5.43百万美元,资产负债比为1.54,流动比率为3.49。机构评级:截至2024年11月17日,当前有10家机构对美国血液技术目标价做出预测,其中目标均价为110.80美元,其中最低目标价为85.00美元,最高目标价为125.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000019abc78df6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000019abc78df6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124602679","title":"异动解读 | 美国血液技术财报超预期 股价大涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124602679","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124602679?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:08","pubTimestamp":1731035333,"startTime":"0","endTime":"0","summary":"周二,医疗器械制造商美国血液技术公司(HAE)公布了2024财年第三季度财报,超出市场预期,公司股价当日大涨7.47%,引发市场关注。\n\n财报显示,美国血液技术第三季度调整后每股收益为1.12美元,高于分析师平均预期的1.07美元。该公司本季度营收同比增长8.6%,达到3.4551亿美元,虽略低于预期的3.4265亿美元,但整体表现依然出色。\n\n分析师对美国血液技术的长期前景持乐观态度。目前分析师平均给予该公司\"买入\"评级,预计其未来12个月股价目标中位数为113.5美元。分析人士认为,作为医疗设备和用品行业的龙头企业,该公司在技术、研发和渠道优势等多方面具备良好发展潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.haemonetics.com","stockEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.1708},{"period":"3month","weight":0.3051},{"period":"6month","weight":0.7287},{"period":"1year","weight":0.9009},{"period":"ytd","weight":0.2831}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Haemonetics Corporation于1971年根据马萨诸塞州法律成立,是一家医疗器械公司。该公司是一家致力于提高医疗保健质量、效果和效率的全球医疗技术公司,运营三个主要报告分部:血浆、血库和医院。公司的创新解决方案包括医院技术、端到端血浆采集技术以及帮助血库采集急需血液成分的产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.02136},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.014099},{"month":3,"riseRate":0.657143,"avgChangeRate":0.017598},{"month":4,"riseRate":0.485714,"avgChangeRate":-0.022035},{"month":5,"riseRate":0.542857,"avgChangeRate":0.020817},{"month":6,"riseRate":0.611111,"avgChangeRate":0.024046},{"month":7,"riseRate":0.666667,"avgChangeRate":0.021448},{"month":8,"riseRate":0.722222,"avgChangeRate":0.026443},{"month":9,"riseRate":0.5,"avgChangeRate":0.012738},{"month":10,"riseRate":0.514286,"avgChangeRate":-0.005196},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046958},{"month":12,"riseRate":0.571429,"avgChangeRate":0.023019}],"exchange":"NYSE","name":"美国血液技术","nameEN":"Haemonetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国血液技术(HAE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国血液技术,HAE,美国血液技术股票,美国血液技术股票老虎,美国血液技术股票老虎国际,美国血液技术行情,美国血液技术股票行情,美国血液技术股价,美国血液技术股市,美国血液技术股票价格,美国血液技术股票交易,美国血液技术股票购买,美国血液技术股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国血液技术(HAE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}